Clinical trial
A Randomized, Active-controlled, Double-blind, Parallel, Multi Center, Phase 3 Study to Evaluate the Efficacy and Safety of Co-administrated ATB-1011 and ATB-1012 in Patients With Essential Hypertension and Type II Diabetes Mellitus
NCT05573477 is registered in ClinicalTrials.gov with Autotelicbio as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Active-controlled, Double-blind, Parallel, Multi Center, Phase 3 Study to Evaluate the Efficacy and Safety of Co-administrated ATB-1011 and ATB-1012 in Patients With Essential Hypertension and Type II Diabetes Mellitus
- Lead sponsor
- Autotelicbio
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- November 16, 2022
- Completion date
- February 28, 2026
- Enrollment
- 255 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.